frontier-banner
Frontiers
Home>Frontiers>

Antibiotics | Applications of Bacteriophages in Medicine and Biotechnology

Antibiotics | Applications of Bacteriophages in Medicine and Biotechnology
--

This article systematically reviews the historical development of bacteriophage research over the past century, focusing on their diverse applications in molecular biology, phage therapy, bacterial detection, food safety, and wastewater purification. It also highlights the potential of phage therapy in combating antibiotic resistance and discusses recent advancements in personalized medicine and biotechnology.

 

Literature Overview
The article, titled 'A Century of Bacteriophages: Insights, Applications, and Current Utilization,' published in the Antibiotics journal, reviews the historical progression of phage research, their structural diversity, and applications across multiple fields, including phage therapy, molecular biology tools, food safety control, and wastewater remediation. It further delves into the significance of phage therapy in modern medicine, especially in the context of increasing antibiotic resistance. Due to their high host specificity, potential for genetic engineering, and ability to synergize with antibiotics, bacteriophages have become a focal point in the development of novel antimicrobial treatments.

Background Knowledge
Bacteriophages are viruses that infect bacteria and, due to their high host specificity, have emerged as critical tools in combating drug-resistant bacterial infections. Since their discovery, phages have played a pivotal role in biological research, notably in the Hershey-Chase experiment that confirmed DNA as the genetic material. Recently, with the rise of multidrug-resistant bacterial strains, phage therapy has regained attention. However, challenges such as immunogenicity, standardization, and regulatory frameworks remain barriers to clinical application. Despite this, several clinical trials (e.g., PHAGOBURN, PhagoDAIR I) have demonstrated promising results regarding the safety and efficacy of phage therapy. Moreover, phage-derived technologies, such as CRISPR-Cas systems and phage display, have become integral to modern biomedical research. In food safety, phages like Listex P100 have received FDA approval for use in controlling Listeria contamination. Phage applications in wastewater treatment and environmental decontamination, particularly in hospital and agricultural settings, also show significant promise.

 

 

Research Methods and Experiments
This article employs a literature review approach to systematically examine the classification, life cycle, host specificity, genome stability, and application potential of bacteriophages. It also discusses clinical trials involving phage therapy, including the use of nebulized phages to treat multidrug-resistant P. aeruginosa infections, the synergistic effects of combining phages with antibiotics to improve clearance rates, and localized phage applications in burn patients. Additionally, the article provides a detailed analysis of phage applications in molecular biology, such as restriction modification systems, phage display, gene cloning tools (λ phage vectors), and next-generation sequencing technologies (PacBio).

Key Conclusions and Perspectives

  • Phage therapy demonstrates safety and efficacy in treating multidrug-resistant infections, particularly in localized applications such as those involving burn patients and bone-joint infections.
  • Combining phages with antibiotics enhances antimicrobial activity and reduces the emergence of resistant bacterial strains.
  • Phage display technology is widely used in vaccine development, antibody screening, and the design of drug delivery systems.
  • Genetic engineering of phages (e.g., CRISPR-enhanced phages) offers novel strategies for treating infections such as those caused by M. abscessus.
  • Phage applications in food safety, wastewater treatment, and environmental decontamination have already reached practical implementation stages.

Research Significance and Prospects
Phage therapy is gradually re-entering the mainstream medical discourse, especially in response to the escalating antibiotic resistance crisis. Future research should focus on standardizing phage preparation, establishing regulatory frameworks, and exploring the mechanisms of phage-host interactions. Advances in engineered phages, combination phage therapies, and phage-based drug delivery systems will expand their applications in precision medicine and environmental management.

 

 

Conclusion
As one of the most abundant biological entities on Earth, bacteriophages offer a versatile solution to the growing challenge of antibiotic resistance. This article summarizes the historical evolution of phage research, their applications in molecular biology and therapeutic contexts, and recent developments in clinical trials. The personalization, safety, and synergistic antimicrobial mechanisms of phage therapy provide promising directions for future anti-infective strategies. Although challenges in standardization and regulation remain, continuous innovation in biotechnology, including phage display, gene editing tools, and vaccine delivery systems, highlights the growing importance of phages in modern medicine.

 

Reference:
Sadika Dkhili, Miguel Ribeiro, and Karim Ben Slama. A Century of Bacteriophages: Insights, Applications, and Current Utilization. Antibiotics.
Antibody Design (RFantibody)
RFantibody utilizes RFdiffusion and RoseTTAFold2 to fine-tune the structures of natural antibodies, specifically for antibody structure design and prediction, supporting the design of single-domain antibodies (VHH). It is capable of designing antibody structures with high binding affinity based on specified antigen epitopes. The design process is as follows: * Given the antibody framework structure and the target antigen structure, binding hotspots can be specified. * Using the diffusion model technique of RFdiffusion, the antibody structure is progressively "denoised" and optimized to design CDR loops that bind to the epitopes of the target antigen. * CDR loop sequences are designed using ProteinMPNN4, achieving an amino acid recovery rate of 52.4%. * The structure of the antibody-antigen complex is predicted and screened using the fine-tuned RoseTTAFold2.